LivaNova PLC
LIVN
Rang in Aktien
#3841
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Aktienkurs
$78.37
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$4.31B
Veränderung (1 Tag)
1.02%
Veränderung (1 Jahr)
44.86%
Land
GB
Handel LivaNova PLC (LIVN)
Kategorie
Healthcare
EPS für LivaNova PLC (LIVN)
EPS zum June 2026 TTM: $3.45
Laut den aktuellen Finanzberichten und dem Aktienkurs von LivaNova PLC beträgt das aktuelle EPS des Unternehmens (TTM) $3.45. Am Ende des Jahres 2023 betrug das EPS $0.33 eine Steigerung gegenüber dem EPS von 2022, das $-1.61 betrug.
EPS-Verlauf von LivaNova PLC von 2000 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $3.45 | 194.87% |
| 2024 | $1.17 | 254.55% |
| 2023 | $0.33 | -120.50% |
| 2022 | $-1.61 | -39.93% |
| 2021 | $-2.68 | -62.04% |
| 2020 | $-7.06 | 119.25% |
| 2019 | $-3.22 | -17.65% |
| 2018 | $-3.91 | 651.92% |
| 2017 | $-0.52 | -59.69% |
| 2016 | $-1.29 | -158.90% |
| 2015 | $2.19 | 8.42% |
| 2014 | $2.02 | 20.24% |
| 2013 | $1.68 | 29.23% |
| 2012 | $1.30 | -22.16% |
| 2011 | $1.67 | -40.99% |
| 2010 | $2.83 | 183.00% |
| 2009 | $1.00 | -356.41% |
| 2008 | $-0.39 | -80.60% |
| 2007 | $-2.01 | -15.19% |
| 2006 | $-2.37 | 364.71% |
| 2005 | $-0.51 | -275.86% |
| 2004 | $0.29 | 20.83% |
| 2003 | $0.24 | -119.83% |
| 2002 | $-1.21 | 611.76% |
| 2000 | $-0.17 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $3.11 | -9.86% |
US
|
|
| $3.59 | 4.06% |
IE
|
|
| $9.73 | 182.03% |
US
|
|
| $2.48 | -28.12% |
US
|
|
| - | - |
DE
|
